Inclusion Criteria

- INCLUSION CRITERIA:

Patients must have been treated on the National Cancer Institute (NCI) trial 06-C-0064
(NCT00271609); bevacizumab alone for recurrent gliomas and now have evidence for tumor
progression by magnetic resonance imaging (MRI) scan.

Patients with histologically proven intracranial malignant glioma will be eligible for
this protocol. Malignant glioma include glioblastoma multiforme (GBM), gliosarcoma,
anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed
oligoastrocytoma (AMO), or malignant astrocytoma NOS (not otherwise specified).

Patients must have evidence for tumor progression by MRI or computed tomography (CT) scan.
This scan should be performed within 14 days prior to registration and on a fixed dose of
steroids for at least 5 days. If the steroid dose is increased between the date of
imaging and registration a new baseline magnetic resonance (MR)/CT is required. The same
type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for
tumor measurement.

Patients must be greater than or equal to 18 years old, and with a life expectancy greater
than 8 weeks.

All patients or their previously designated durable power of attorney (DPA) (if the
patient is deemed by the treating physician to be impaired or questionably impaired in
such a way that the ability of the patient to give informed consent is questionable) must
sign an informed consent indicating that they are aware of the investigational nature of
this study.

Patients must have a Karnofsky performance status of greater than or equal to 60.

Patients must not be more than 4 weeks since their last bevacizumab treatment and may have
received no form of treatment (i.e. radiation, chemotherapy, surgery, investigational
therapy) for their progressive tumor between their last bevacizumab treatment and
enrollment of this companion trial.

Patients must have adequate bone marrow function (white blood cell (WBC) greater than or
equal 3,000/microl, absolute neutrophil count (ANC) greater than or equal to1,500/mm^3,
platelet count of greater than to or equal 100,000/mm^3), and hemoglobin greater than or
equal to 10 gm/dl), adequate liver function (serum glutamic oxaloacetic transaminase
(SGOT) and bilirubin less than 2.5 times upper limits of normal (ULN)), and adequate renal
function (creatinine less than 1.5 mg/dL and/or creatinine clearance greater than or equal
to 60 cc/min) before starting therapy. These tests must be performed within 14 days prior
to registration. Eligibility level for hemoglobin may be reached by transfusion.

Patients must not have any significant medical illnesses that in the investigator's
opinion cannot be adequately controlled with appropriate therapy or would compromise the
patients' ability to tolerate this therapy.

This study was designed to include women and minorities, but was not designed to measure
differences of intervention effects. Males and females will be recruited with no
preference to gender. No exclusion to this study will be based on race.

Urine protein should be screened by dipstick or urine analysis for Urine Protein
Creatinine (UPC) ratio. For proteinuria greater than or equal to 1+ or urine
protein:creatinine UPC ratio greater than 1.0, 24-hour urine protein should be obtained
and the level should be less than 1000 mg for patient enrollment.

Subjects must be willing and able to practice adequate contraception.

EXCLUSION CRITERIA:

Concurrent use of other standard chemotherapeutics or investigative agents.

Patients who have an active infection.

Pregnant (positive pregnancy test) or nursing women. Both fertile men and women must
agree to use adequate contraceptive measures during study therapy and for at least 6
months after the completion of bevacizumab therapy.

Concurrent anti-coagulation or anti-platelet medication (including aspirin, non-steroidal
anti-inflammatories, cyclooxygenase-2 (COX-2) inhibitors).

Serious or non-healing wound, ulcer or bone fracture.

History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 28 days.

Invasive procedures defined as follows:

- Major surgical procedure, open biopsy or significant traumatic injury within 28 days
prior to Day 1 therapy

- Anticipation of need for major surgical procedures during the course of the study

- Core biopsy within 7 days prior to day (D)1 therapy

Patients with clinically significant cardiovascular disease:

- History of cerebrovascular accident (CVA) within 6 months

- Uncontrolled hypertension (greater than 150/100 mmHg)

- Myocardial infarction or unstable angina within 6 months

- New York heart association grade II or greater congestive heart failure

- Serious cardiac arrhythmia requiring medication

- Unstable angina pectoris

- Clinically significant peripheral vascular disease

Clinical evidence of bleeding diathesis or coagulopathy.

Patients with known hypersensitivity of Chinese hamster ovary cell products or other
recombinant human antibodies.